Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate PureTech Health plc before investing.

In this article, we go over a few key elements for understanding PureTech Health plc’s stock price such as:

• PureTech Health plc’s current stock price and volume
• Why PureTech Health plc’s stock price changed recently
• Upgrades and downgrades for PRTC from analysts
• PRTC’s stock price momentum as measured by its relative strength

About PureTech Health plc (PRTC)

Before we jump into PureTech Health plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Want to learn more about PureTech Health plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about PureTech Health plc.

PureTech Health plc’s Stock Price as of Market Close

As of November 28, 2025, 11:21 AM, CST, PureTech Health plc’s stock price was $16.700.

PureTech Health plc is up 4.38% from its previous closing price of $16.000.

During the last market session, PureTech Health plc’s stock traded between $16.580 and $16.830. Currently, there are approximately 239.96 million shares outstanding for PureTech Health plc.

PureTech Health plc’s price-earnings (P/E) ratio is currently at 82.7, which is high compared to the Biotechnology industry median of 19.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

PureTech Health plc Stock Price History

PureTech Health plc’s (PRTC) price is currently down 6.05% so far this month.

During the month of November, PureTech Health plc’s stock price has reached a high of $17.850 and a low of $0.000.

Over the last year, PureTech Health plc has hit prices as high as $23.690 and as low as $13.300. Year to date, PureTech Health plc’s stock is down 9.53%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused PureTech Health plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were analysts who downgraded PureTech Health plc’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate PureTech Health plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on PureTech Health plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

PureTech Health plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about PureTech Health plc (PRTC) by visiting AAII Stock Evaluator.

Relative Price Strength of PureTech Health plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, PureTech Health plc has a weighted four-quarter relative price strength of -10.00%, which translates to a Momentum Score of 25 and is considered to be Weak.

Want to learn more about how PureTech Health plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

PureTech Health plc Stock Price: Bottom Line

As of November 28, 2025, PureTech Health plc’s stock price is $16.700, which is up 4.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like PureTech Health plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.